Affiliation:
1. Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India
Abstract
High mobility group box-1 (HMGB1) mainly belongs to the non-histone DNA-binding protein.
It has been studied as a nuclear protein that is present in eukaryotic cells. From the HMG family,
HMGB1 protein has been focused particularly for its pivotal role in several pathologies. HMGB-1 is
considered as an essential facilitator in diseases such as sepsis, collagen disease, atherosclerosis, cancers,
arthritis, acute lung injury, epilepsy, myocardial infarction, and local and systemic inflammation.
Modulation of HMGB1 levels in the human body provides a way in the management of these diseases.
Various strategies, such as HMGB1-receptor antagonists, inhibitors of its signalling pathway, antibodies,
RNA inhibitors, vagus nerve stimulation etc. have been used to inhibit expression, release or activity
of HMGB1. This review encompasses the role of HMGB1 in various pathologies and discusses
its therapeutic potential in these pathologies.
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献